


Sygnia 



Sygnia Itrix Solactive Healthcare 150 ETF

A high risk, passively managed index tracking fund whose objective is to replicate the price and yield performance of the Solactive Developed Markets Healthcare 150 Index.

Risk profile



Investment objective and strategy

The objective of the Sygnia Itrix Solactive Healthcare 150 ETF is to provide an investment vehicle that gives easy access to investors who want to achieve long term capital appreciation in tracking the performance of the Solactive Developed Markets Healthcare 150 Index (.SDMH150P) ("benchmark index"). The Sygnia Itrix Solactive Healthcare 150 ETF is a high risk, passively managed index tracking fund, registered as a Collective Investments Scheme, and is listed on the Johannesburg Stock Exchange as an Exchange Traded Fund with the objective is to replicate the price and yield performance of the Solactive Developed Markets Healthcare 150 Index as closely as possible by physically holding a portfolio of securities equivalent to the basket of securities comprising the Index and in similar weightings to that of the Index. The Solactive Developed Markets Healthcare 150 Index tracks the performance of the largest 150 companies from the developed market Healthcare Industry and is based on the Solactive Global Benchmark Series. Constituents are selected and weighted based on free-float market capitalisation. Index Performance data can be sourced from Solactive, Reuters and at www.sygnia.co.za.

Risk profile

The Fund has a 100% strategic allocation to global equities. The risk in the Fund is managed by spreading investments across countries and individual shares. However, the structure of the Fund is dictated by the composition of the Solactive Developed Markets Healthcare 150 Index. The focus on the largest, more liquid companies provides an added benefit in terms of risk management.

What the fund invests in

Top 10 Holdings	Percentage	Allocation
Eli Lilly Ord Shs	6.7	██████████
UnitedHealth Group Ord Shs	6.6	██████████
Johnson & Johnson Ord Shs	5.1	██████████
Novo Nordisk Ord Shs Class B	4.4	██████████
Merck & Co Ord Shs	3.7	██████████
AbbVie Ord Shs	3.7	██████████
Roche Holding Par Shs	2.8	██████████
Thermo Fisher Scientific Ord Shs	2.8	██████████
Novartis Ord Shs	2.7	██████████
Astrazeneca Ord Shs	2.7	██████████

Who should invest?

The Sygnia Itrix Solactive Healthcare 150 ETF has a high risk profile and is designed to track the Index as closely as possible by buying securities included in the Index at similar weighting as they are included in the Index. It is a suitable investment for investors seeking higher returns, those who are willing to tolerate higher volatility and investors who aim to maximise capital accumulation over a longer-term time horizon. The investment is also suitable for investors who wish to maximise their returns in the most cost-effective manner without the need to select asset managers or take on the risk of active and subjective investment decision making processes.

Fees

Management Fee	0.44% p.a. (excl. VAT)
Other Expenses	0.01%
VAT	0.07%
Total Expense Ratio (TER)	0.51% (Dec 2023)
Transaction Costs (TC)	0.01% (Dec 2023)
Total Investment Charge (TIC)	0.53% (Dec 2023)

A higher TER does not necessarily imply a poor return, nor does a low TER imply a good return. The current TER may not necessarily be an accurate indication of future TER's. Transaction Costs are a necessary cost in administering the Financial Product and impacts Financial Product returns. It should not be considered in isolation as returns may be impacted by many other factors over time including market returns, the type of Financial Product, the investment decisions of the investment manager and the TER.

Portfolio managers

Sygnia Asset Management (Pty) Ltd

The management of investments is outsourced to Sygnia Asset Management (Pty) Ltd (FSP 873), an authorised Financial Services Provider under the Financial Advisory and Intermediary Services Act, 2002.

Key facts

Fund Launch Date

6 August 2021

Fund Size

R 673 Million

Regulation 28

Non-Compliant

Benchmark

Solactive Developed Markets Healthcare 150 Index

Minimum investment period

5+ years

Disclosures

The Sygnia Group is a member of the Association for Savings and Investment SA. Sygnia Itrix (RF) (Pty) Ltd is a registered and approved Manager under the Collective Investment Schemes Control Act, 2002. Sygnia Asset Management (Pty) Limited (FSP 873), an authorised financial services provider, is the appointed investment manager of the Fund. Sygnia Itrix does not provide any guarantee with respect to the capital or return of the portfolio. Collective Investment Schemes (CIS) are generally medium to long-term investments. Collective investment schemes are traded at ruling prices and can engage in borrowing and scrip lending. The value of investments/units may go down as well as up and past performance is not necessarily an indicator of future performance. ETFs trade on stock exchanges and may therefore incur additional costs associated with listed securities. Unlike a unit trust, which can be bought or sold only once per day, an ETF can be traded intraday, during exchange trading hours. ETFs may invest in foreign securities, which may be exposed to macroeconomic, settlement, political, tax, liquidity, and foreign exchange risks. Performance is calculated for the portfolio, and the individual investor performance may differ as a result of trading cost, price paid for investment share. Additional information on the Index including its performance and tracking error can be viewed on the relevant Minimum Disclosure Document (MDD) on www.sygnia.co.za. A schedule of fees, charges and where the ETF engages in securities lending activities, information on such securities lending activities may be requested via admin@sfs.sygnia.co.za or 0860 794 642. The complete terms and conditions of your ETF investment are contained in the fund's offering circular, pre-listing statement, programme memorandum and/or supplemental deed and index constituents with prices are published daily on Sygnia's website. The documents/information may be obtained from www.sygnia.co.za or on request from Sygnia. Nothing in this document shall be considered to state or imply that the Fund is suitable for a particular type of investor. All the portfolio options presented are approved collective investment schemes in terms of the Collective Investment Schemes Control Act, No 45 of 2002 ("CISCA"). The Manager has the right to close any portfolios to new investors to manage them more efficiently in accordance with their mandates. A copy of the Minimum Disclosure Document (MDD) is available on our website: www.sygnia.co.za.

Index Disclaimer

The funds or securities referred to herein are not sponsored, endorsed or promoted by Solactive AG, and Solactive AG bears no liability with respect to any such funds or securities or any index on which such funds or securities are based. The complete terms and conditions of your ETF investment are contained in the fund's Offering Circular and Pre-Listing Statement and the relevant Supplement.